Literature DB >> 33314709

Cumulative cancer incidence and mortality after kidney transplantation in Japan: A long-term multicenter cohort study.

Ryoichi Imamura1, Shigeaki Nakazawa1, Kazuaki Yamanaka2, Yoichi Kakuta3, Koichi Tsutahara3, Ayumu Taniguchi1, Masataka Kawamura1, Taigo Kato1, Toyofumi Abe1, Motohide Uemura1, Tetsuya Takao3, Hidefumi Kishikawa2, Norio Nonomura1.   

Abstract

Kidney transplantation is the most promising treatment to improve mortality and life quality in end-stage kidney disease; however, cancer remains a leading cause of death. Several factors including immunosuppressants might be associated with a gradual increase in cumulative cancer incidence after kidney transplantation. Risk factors for cancer and overall and cancer-specific survival were analyzed in 1973 kidney transplant recipients from three study institutions in Japan. The 5-, 10-, 20-, and 30-year overall and cancer-specific survival rates were 93.3%, 88.4%, 78.0%, and 63.6% and 99.4%, 98.0%, 95.3%, and 91.7%, respectively. The overall survival rate was significantly higher and the graft survival rate was significantly lower in recipients without cancer than in those with cancer. Older recipient age, longer dialysis duration before kidney transplantation, and history of transfusion were significant predictors of cancer. Dialysis duration before kidney transplantation was a prognostic factor of overall survival rate. Regarding cancer-specific survival rates, older recipient age and dialysis duration before kidney transplantation were prognostic factors of worse cancer-specific survival rates. The type of immunosuppressant was not associated with an increased cancer rate. Aggressiveness of immunosuppressant regimens or potent immunosuppressants might improve graft survival rate while inducing de novo cancer after kidney transplantation. Older age and longer dialysis duration before kidney transplantation were risk factors of cancer-specific survival rate.
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Entities:  

Keywords:  aggressiveness of immunosuppressant regimens; de novo cancer; dialysis duration; kidney transplantation; post-transplant lymphoproliferative disorders

Mesh:

Substances:

Year:  2020        PMID: 33314709      PMCID: PMC7982608          DOI: 10.1002/cam4.3636

Source DB:  PubMed          Journal:  Cancer Med        ISSN: 2045-7634            Impact factor:   4.452


  34 in total

Review 1.  Malignancy in renal transplantation.

Authors:  Christian Morath; Martina Mueller; Hartmut Goldschmidt; Vedat Schwenger; Gerhard Opelz; Martin Zeier
Journal:  J Am Soc Nephrol       Date:  2004-06       Impact factor: 10.121

2.  Cause of death with graft function among renal transplant recipients in an integrated healthcare system.

Authors:  Joseph Kahwaji; Suphamai Bunnapradist; Jin-Wen Hsu; Mohammed L Idroos; Ryszard Dudek
Journal:  Transplantation       Date:  2011-01-27       Impact factor: 4.939

3.  Incidence of cancer in kidney-transplant recipients: a long-term cohort study in a single center.

Authors:  Hermina C Wisgerhof; Lydia G M van der Geest; Johan W de Fijter; Geert W Haasnoot; Frans H J Claas; Saskia le Cessie; Rein Willemze; Jan N Bouwes Bavinck
Journal:  Cancer Epidemiol       Date:  2010-07-31       Impact factor: 2.984

4.  Higher calcineurin inhibitor levels predict better kidney graft survival in patients with de novo donor-specific anti-HLA antibodies: a cohort study.

Authors:  Marc-Antoine Béland; Isabelle Lapointe; Réal Noël; Isabelle Côté; Eric Wagner; Julie Riopel; Eva Latulippe; Olivier Désy; Stéphanie Béland; Ciara N Magee; Isabelle Houde; Sacha A De Serres
Journal:  Transpl Int       Date:  2017-03-05       Impact factor: 3.782

5.  Immune phenotype predicts risk for posttransplantation squamous cell carcinoma.

Authors:  Robert P Carroll; David San Segundo; Kevin Hollowood; Teresa Marafioti; Taane G Clark; Paul N Harden; Kathryn J Wood
Journal:  J Am Soc Nephrol       Date:  2010-01-28       Impact factor: 10.121

6.  Risk factors for malignancy in Japanese renal transplant recipients.

Authors:  Tetsuya Imao; Naotsugu Ichimaru; Shiro Takahara; Yukito Kokado; Masayoshi Okumi; Ryoichi Imamura; Yukiomi Namba; Yoshitaka Isaka; Norio Nonomura; Akihiko Okuyama
Journal:  Cancer       Date:  2007-05-15       Impact factor: 6.860

7.  Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients.

Authors:  Gerhard Opelz; Cord Naujokat; Volker Daniel; Peter Terness; Bernd Döhler
Journal:  Transplantation       Date:  2006-05-15       Impact factor: 4.939

8.  Complement-binding anti-HLA antibodies and kidney-allograft survival.

Authors:  Alexandre Loupy; Carmen Lefaucheur; Dewi Vernerey; Christof Prugger; Jean-Paul Duong van Huyen; Nuala Mooney; Caroline Suberbielle; Véronique Frémeaux-Bacchi; Arnaud Méjean; François Desgrandchamps; Dany Anglicheau; Dominique Nochy; Dominique Charron; Jean-Philippe Empana; Michel Delahousse; Christophe Legendre; Denis Glotz; Gary S Hill; Adriana Zeevi; Xavier Jouven
Journal:  N Engl J Med       Date:  2013-09-26       Impact factor: 91.245

9.  Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients.

Authors:  A C Webster; J C Craig; J M Simpson; M P Jones; J R Chapman
Journal:  Am J Transplant       Date:  2007-07-19       Impact factor: 8.086

10.  Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQITM) conference.

Authors:  Michael Abecassis; Stephen T Bartlett; Allan J Collins; Connie L Davis; Francis L Delmonico; John J Friedewald; Rebecca Hays; Andrew Howard; Edward Jones; Alan B Leichtman; Robert M Merion; Robert A Metzger; Francoise Pradel; Eugene J Schweitzer; Ruben L Velez; Robert S Gaston
Journal:  Clin J Am Soc Nephrol       Date:  2008-02-06       Impact factor: 8.237

View more
  2 in total

1.  Everolimus Reduces Cancer Incidence and Improves Patient and Graft Survival Rates after Kidney Transplantation: A Multi-Center Study.

Authors:  Ryoichi Imamura; Ryo Tanaka; Ayumu Taniguchi; Shigeaki Nakazawa; Taigo Kato; Kazuaki Yamanaka; Tomoko Namba-Hamano; Yoichi Kakuta; Toyofumi Abe; Koichi Tsutahara; Tetsuya Takao; Hidefumi Kishikawa; Norio Nonomura
Journal:  J Clin Med       Date:  2022-01-04       Impact factor: 4.241

2.  Carcinogenicity risk associated with tacrolimus use in kidney transplant recipients: a systematic review and meta-analysis.

Authors:  Liangping Wang; Kuifen Ma; Yao Yao; Liang Yu; Jianyong Wu; Qingwei Zhao; Ziqi Ye
Journal:  Transl Androl Urol       Date:  2022-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.